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KIBRA genetic polymorphism influences episodic memory in later life, but does 
not increase the risk of mild cognitive impairment 
Abstract 
A common T→C polymorphism of the KIBRA gene has been recently associated with worse performance 
on tests of episodic memory. This should aimed to determine whether older adults with the KIBRA CC 
genotype (1) have worse episodic memory than T-allele carriers and, (2) are more likely to express the 
phenotype of amnestic mild cognitive impairment (MCI). Our Cross-sectional investigation of 312 adults 
aged 50-89 years free of dementia included genotyping of the KIBRA rs17070145 gene and the 
assessment of episodic memory to Establish a Registry for Alzheimer's Disease (CERAD). Participants 
were considered to have MCI if their memory scores were 1.5 standard deviations below the mean norm 
for the population. 138/312 participants carried the KIBRA CC genotype. Their immediate and delayed 
recall scores were significantly lower than the scores of carriers of the T allele (P < 0.05; adjusted for age, 
gender and pre-morbid IQ), although the effect size of the CC genotype was weak (0.2). Amongst our 
volunteers, 133 had MCI, of whom 63 (47.4%) had the CC genotype. There was no association between 
KIBRA genotype and MCI phenotype (TT/CT versus CC; adjusted odds ratio = 1.70, 95%CI = 0.74, 3.90). 
We concluded that the KIBRA T→C polymorphism contributes to modulate episodic memory amongst 
community-dwelling older adults free of dementia, but plays no obvious role in the phenotypic expression 
of MCI. Future studies should aim to clarify the long term implications of this polymorphism on cognitive 
function and to identify other genes involved in the modulation of memory that might confer greater risk 
of MCI in later life. 
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Introduction
Memory is a fundamental cognitive ability that enables humans
to learn and remember information, contributing to fill people’s
lives with meaning, continuity and context. Memory consists of
procedural and declarative systems, with the latter including
semantic and episodic memory [1]. Episodic memory repre-
sents a set of cognitive functions involved in the encoding, 
storage and retrieval of information about facts or events that
happen within a particular time and place. There is now evi-
dence that episodic memory is a polygenic cognitive trait with
estimated heritability of 50% in twin studies [2]. Recently,
Papassotiropoulos and colleagues [3] showed that a single
nucleotide polymorphism (T→C) within the ninth intron of the
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Abstract
A common T→C polymorphism of the KIBRA gene has been recently associated with worse performance on tests of episodic memory.
This should aimed to determine whether older adults with the KIBRA CC genotype (1) have worse episodic memory than T-allele carriers
and, (2) are more likely to express the phenotype of amnestic mild cognitive impairment (MCI). Our Cross-sectional investigation of 
312 adults aged 50–89 years free of dementia included genotyping of the KIBRA rs17070145 gene and the assessment of episodic mem-
ory to Establish a Registry for Alzheimer’s Disease (CERAD). Participants were considered to have MCI if their memory scores were 
1.5 standard deviations below the mean norm for the population. 138/312 participants carried the KIBRA CC genotype. Their immediate
and delayed recall scores were significantly lower than the scores of carriers of the T allele (P < 0.05; adjusted for age, gender and pre-
morbid IQ), although the effect size of the CC genotype was weak (0.2). Amongst our volunteers, 133 had MCI, of whom 63 (47.4%)
had the CC genotype. There was no association between KIBRA genotype and MCI phenotype (TT/CT versus CC; adjusted odds ratio =
1.70, 95%CI = 0.74, 3.90). We concluded that the KIBRA T→C polymorphism contributes to modulate episodic memory amongst com-
munity-dwelling older adults free of dementia, but plays no obvious role in the phenotypic expression of MCI. Future studies should aim
to clarify the long term implications of this polymorphism on cognitive function and to identify other genes involved in the modulation
of memory that might confer greater risk of MCI in later life.
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KIBRA gene (rs17070145) influences episodic memory and
modulates the activation of the hippocampus during memory
retrieval. They studied three independent samples of adults and
found that those with the CC genotype had significantly worse
scores on tests of verbal and visual episodic memory than CT
and TT carriers. The same pattern of memory performance
according to KIBRA polymorphisms was observed in 64 healthy
older adults from Germany [4], but data about the relevance of
this polymorphism in later life remains sparse and it is unclear
whether this T→C substitution contributes to modulate episodic
memory in older people.
The performance of adults in tests of episodic memory
declines with increasing age.5 In some, these deficits do not seem
to be progressive in nature, but in others they are the precursors
of further cognitive decline and dementia [6, 7]. The concept of
‘mild cognitive impairment’ (MCI) was introduced to describe a
group of people who are at increased risk of developing dementia
as they age [7]. Typically, people with MCI show normal age-
adjusted general cognitive abilities, but display significant deficits
in tests of episodic memory [7]. Progress to dementia ranges
from 5 to 16% per annum [8], but epidemiological evidence indi-
cates that most people with MCI do not progress to a full-blown
dementia syndrome 2 years after diagnosis [9]. These results sug-
gest that the genetic determinants of MCI and dementia pheno-
types are not necessarily the same, and raise the possibility that
the KIBRA T→C polymorphism has a role to play in the develop-
ment of MCI in later life. 
We designed this study to: (1) replicate the findings of
Papassotiropoulos et al. in an independent sample of community-
dwelling older adults and, (2) determine if the MCI phenotype is
associated with T→C polymorphism of the KIBRA gene. 
Methods
Participants
Three hundred and thirty-six adults volunteered to take part in this study.
They were recruited through advertisement in the local media and from
the local Memory Clinic, and were included if they were aged 50 years or
older, had Mini-Mental State Examination (MMSE) score 24 [10] and
Clinical Dementia Rating (CDR)  0.5 [11],and showed no evidence of
dementia according to the DSM-IV diagnostic criteria (APA, 1994) [12].
We excluded people with self-reported prior clinical history of strokes,
severe visual or hearing impairment, a score greater than 18 on the Beck
Depression Inventory [13], and those who did not provide written
informed consent. The Ethics Committee of the Royal Perth Hospital
approved this research project. 
Assessment procedure
Three hundred and twelve people were deemed suitable for inclusion in
the study (DNA samples were not available for 2 subjects and another
22 volunteers were excluded because they had a MMSE<24 or met
criteria for the diagnosis of dementia). Their mean age was 71.2 years
(SD = 7.6; range = 50–89) and 50.0% were male. Information on eth-
nicity was not collected in a structured manner, but we estimated that
98% of participants were of Caucasian background. Participants under-
went assessment with the Cambridge Contextual Reading Test (CCRT),
which produces a valid measure of the pre-morbid intelligence quotient
(IQ) [14] and the cognitive battery of the Consortium to Establish a
Registry for Alzheimer’s Disease (CERAD) [15]. The CERAD is a neu-
ropsychological battery that consists of tests assessing verbal fluency,
naming, praxis, immediate and delayed recall (episodic memory), and
recognition. Normative data is available for each one of the tests [15].
For the purposes of this study, we grouped participants under the head-
ing of MCI if they had an immediate or delayed recall score on the
CERAD that was 1.5 standard deviations below the norm and offered an
affirmative answer to the question: ‘Do you have any difficulty with
your memory?’ 
Genotyping of the KIBRA gene
Participants donated a blood sample for extraction of DNA and genotyping
of the KIBRA SNP rs17070145 using restriction polymerase chain reac-
tion-fragment length polymorphism (PCR-RFLP) analysis. The relevant
primers were designed using the web-based Primer3 software [16]:
17070145F2- tttactcccagcacacacctc and 17070145Rev2 - cacaatgaacaag-
gctgtgg. The PCR reactions contained 12.5ng genomic DNA, 2pmol each
primer, 100uM each dNTP, 1X Taq polymerase buffer and 0.5U Taq
Polymerase (Qiagen) in a final volume of 10ul. Cycling conditions com-
prised an initial denaturation of 95°C for 5 min., followed by 35 cycles of
denaturation at 94°C for 30 sec., annealing at 59°C for 30 sec., extension
at 72°C for 30 sec., and a final elongation at 72°C for 7 min. Restriction
enzyme digestion of the 160bp PCR product was performed with 2.5U of
the restriction enzyme MnlI (New England Biolabs) according to manufac-
turer’s directions. The digested products were separated by 2.5% agarose
gel electrophoresis and visualized with ethidium bromide staining. A frag-
ment size of 122bp, represented the T allele (28 and 10bp fragments not
visible) and 68bp and 54bp the C allele (28 and 10bp fragments not visible).
Test for Hardy-Weinberg equilibrium showed that the genotypic distri-
bution of rs17070145 did not deviate from expectation (exact probability,
P = 0.524).
Analysis of data
Data were analysed with the statistical package Stata release 9.2
(StataCorp, College Station, Texas). We used graphic methods to inves-
tigate the distribution of the data and statistic summary measures to
describe study variables, including proportions, means and correspon-
ding 95% confidence interval (95%CI), and medians with corresponding
inter-quartile ranges (IQR). We used Pearson chi-square statistic (2) to
evaluate the distribution of categorical variables (such as gender)
according to the KIBRA polymorphism, Student’s t-test to compare
means and Mann-Whitney test z-statistic to compare the distribution of
ranked data according to KIBRA genotype. Analyses of co-variance were
used to determine between-group differences on measures of episodic
memory taking into account age and pre-morbid IQ. We used logistic
regression to ascertain the risk (odds ratio) of MCI according to KIBRA
rs17070145 genotype, taking into account the effects of age, gender and
pre-morbid IQ. The Breusch-Pagan / Cook–Weisberg test for het-
eroskedasticity showed that our data met the assumptions of
homoskedasticity. Residuals from the regression models were normally
distributed (Shapiro–Wilk P > 0.28 for all tests).  was set at 5% and all
P-values reported are two-tailed.
Results
There were 138, 143 and 31 CC, CT and TT KIBRA rs17070145
carriers in the sample. Table 1 summarizes their clinical and neu-
ropsychological characteristics. People with CC genotype were
younger than CT/TT participants (P=0.008). There was also a non-
significant trend for CC carriers to have higher pre-morbid IQ
(P=0.152). Subjects with the CC genotype of the KIBRA gene had
lower scores than their counterparts on immediate and delayed
recall, as well as recognition (Table 1). The effect size of KIBRA CC
genotype on delayed memory scores was 0.2 (adjusted for age,
gender and pre-morbid IQ).
One hundred and thirty-six people met the study criteria for
the diagnosis of amnestic MCI, of whom 65 (47.8%) were CC
carriers. The genotypic distribution of the KIBRA gene in this
subsample was in equilibrium (Hardy-Weinberg test, exact prob-
ability, P=1.000). The KIBRA CC genotype was not associated
with a significant increase in the odds of MCI (OR = 1.73, 95%
CI = 0.75, 3.96, P=0.197; adjusted for age, pre-morbid IQ and
gender). We then assessed the effect of the CC genotype on the
memory scores of subjects with MCI. The results of these analy-
ses appear in Table 2. There were no obvious associations
between KIBRA genotype and memory scores. No further analyses
were carried out because of increased risk of type I error and
decreased power.
Discussion
We designed this study to address two questions about the role of
the KIBRA T→C polymorphism on episodic memory. Firstly, we
wished to replicate the original findings of Papassotiropoulos and
colleagues [3] in a new sample of community-dwelling older
adults without dementia. Our results confirmed that people with
the CC genotype have worse episodic memory than carriers of the
T allele. Secondly, we wanted to clarify whether the KIBRA gene
contributed to the expression of the MCI phenotype in adults aged
50 years or over. We found an excess risk of MCI amongst those
with the CC genotype (73%), although this association was not
significant (95%CI of the odds ratio = 0.75, 3.96). 
It is unclear how well our volunteers represent the popula-
tion of adults older than 50 years living in the Australian com-
munity, but an over-representation of people with memory
problems is likely due to the strategies used to recruit partici-
pants. Our study sample had a similar proportion of men and
women, which is in contrast with census data showing an
excess of women in this age group [17]. In addition, the pre-
morbid intelligence quotient of participants was above average.
As IQ and memory scores have a correlation of approximately
0.5 [18] one might expect a lower prevalence of factors that
compromise memory performance among people with above
average IQ, such as the KIBRA CC genotype. The prevalence of
this genotype in our sample was 44.2%, which is not dissimilar
from the 47.5% and 45.3% point prevalence reported by others
Table 1 Clinical and demographic characteristics of older adults according to the KIBRA rs17070145 polymorphism
95%CI: 95% confidence interval, IQ, pre-morbid intelligence quotient; MMSE, mini-mental state examination; IQR, inter-quartile range.
The number of degrees of freedom was 310 for t-tests and 1 for Pearson’s chi-square and F statistic (analysis of co-variance)
*P-value adjusted for the effect of age, gender and pre-morbid IQ
TT/CT (n=174) CC (n=138) Statistic P
Age, mean years (95%CI) 72.2 (71.1, 73.4) 69.9 (68.7, 71.2) t = 2.68 0.008
Female gender, n (%) 90 (51.7) 66  (47.8) chi-square = 0.47 0.494
IQ, mean (95%CI) 115.5 (114.6, 116.4) 116.5  (115.5, 117.4) t = -1.44 0.152
MMSE, median (IQR) 28 (28, 28) 28 (28, 29) z = 0.20 0.839
CERAD immediate recall, mean (95%CI) 18.6 (18.0, 19.3) 18.2 (17.4, 18.9) F = 4.08 0.044*
CERAD delayed recall, mean (95%CI) 5.9 (5.5, 6.2) 5.7 (5.3, 6.1) F = 3.91 0.049*
CERAD recognition, mean (95%CI) 19.2 (18.9, 19.4) 18.9 (18.6, 19.4) F = 5.36 0.021*
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[3, 4]. Moreover, test for Hardy-Weinberg equilibrium revealed
no deviation from the expected genotypic distribution, indicat-
ing that population stratification is unlikely. Finally, the higher IQ
of our participants might have contributed to mitigate the asso-
ciation between KIBRA CC genotype and memory function. We
found that the adjusted effect size of this association in our
sample for delayed recall was 0.2 (unadjusted effect size of 0.1).
Papassotiropoulos and colleagues observed a negative unad-
justed effect size of the CC genotype of approximately 0.7 in
their first Swiss sample, and 0.4 for both the American and the
second Swiss samples [3]. 
Another factor to be considered in the interpretation of our
results relates to the nature of the episodic memory task used in
this and other studies. The episodic memory test of the CERAD
consists of a list of 10 semantically unrelated words that subjects
are asked to read aloud and remember. The immediate recall score
is calculated by adding the total number of words remembered
correctly immediately after each of the three presentation trials
(possible score range: 0–30). Of note, the approach used to cal-
culate CERAD immediate recall scores involves a learning compo-
nent that is likely to be hippocampus dependent. After a delay of
approximately 5 min., subjects are encouraged to remember as
many words as they can (possible score range: 0–10) and, later,
have to recognize the 10 familiar words in a list of 20 words (pos-
sible score range: 0–20). This test is similar to those used by
Papassotiropoulos and colleagues [3], although their assess-
ments were more demanding in terms of the number of items to
be recalled (15–30), time between presentation and recall (5 min.
to 24 hrs), and type of stimulus used (verbal and visual). Hence,
our assessment might have been less sensitive.
Papassotiropoulos and co-workers also found that, compared
to carriers of the T allele, normal adults with the KIBRA CC geno-
type displayed greater functional MRI activation of medial tempo-
ral and frontal lobe structures, as well as inferior parietal lobule
during retrieval of episodic memory information [3]. They con-
cluded that non-carriers of the T allele required more widespread
activation (effort) of memory networks to complete the task.
Similar findings have been reported for people with MCI [19] albeit
not consistently [20]. 
Of interest, Rodriguez-Rodriguez and colleagues [21] found, in
a cross-sectional study of 391 patients with Alzheimer’s disease
(AD) and 428 healthy controls, that carriers of the KIBRA T allele
were more frequent in the AD group. They argued that their find-
ings were in contrast with those of Papassotiopoulos et al. [3],
although the results could be explained by type I error due to mul-
tiple comparisons and survivorship bias leading to the premature
censoring of people with AD and the KIBRA CC genotype. 
This study has the merit of being the first to analyse the impact
of the common KIBRA T→C polymorphism on the phenotypic
expression of amnestic MCI. Typically, people with MCI perform
poorly on tests of episodic memory, but only a relative small pro-
portion progress to a full blown dementia syndrome at follow-up
[9]. This observation suggests that genetic factors other than
those related to dementia modulate the expression of the MCI phe-
notype later in life, although our results indicate that the KIBRA
gene is unlikely to play a prominent role in this process. We did
not find evidence in support of our original hypothesis that CC car-
riers would be at greater risk of MCI (although we did observe a
trend in that direction), nor were we able to show any evidence of
an effect of the gene on the memory scores of older people with
MCI. These results suggest that the effect size of the T→C poly-
morphism decreases with increasing impairment of episodic
memory, and that the KIBRA gene plays all but a limited role after
scores fall below a certain threshold, as is the case in MCI. 
Table 2 Clinical and demographic characteristics of older adults with MCI according to the KIBRA rs17070145 polymorphism
95%CI: 95% confidence interval, IQ, premorbid intelligence quotient; MMSE, mini-mental state examination; IQR: inter-quartile range.
The number of degrees of freedom was 310 for t-tests and 1 for Pearson’s chi-square and F statistic (analysis of co-variance)
*P-value adjusted for the effect of age, gender and premorbid IQ.
TT/CT (n=71) CC (n=65) Statistic p
Age, mean years (95%CI) 72.1 (70.5, 73.7) 69.7 (67.7, 71.6) t = 1.93 0.055
Female gender, n (%) 43 (60.6) 28 (43.1) chi-square = 3.22 0.073
IQ, mean (95%CI) 113.8 (112.4, 115.1) 114.8 (113.6, 116.0) T = -1.13 0.261
MMSE, median (IQR) 28 (27, 28) 27 (27, 28) Z = -0.02 0.984
CERAD immediate recall, mean (95%CI) 15.2 (14.3, 16.0) 15.2 (14.4, 16.0) F = 0.11 0.732*
CERAD delayed recall, mean (95%CI) 4.2 (3.6, 4.7) 4.1 (3.6, 4.6) F = 1.41 0.237*
CERAD recognition, mean (95%CI) 18.5 (18.1, 18.9) 18.2 (17.7, 18.7) F = 1.69 0.196*
In summary, our results confirm that older adults with the
KIBRA CC genotype have slightly worse episodic memory than T-
allele carriers. We also found that the KIBRA gene does not play a
significant role in the phenotypic expression of amnestic MCI.
Future studies should aim to clarify the long term implications of
the KIBRA T(C polymorphism on cognitive function and to identify
other genes involved in the modulation of memory that might con-
fer greater risk of MCI in later life.
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